Latest Regulatory News

PointsBet Holdings Limited updates shareholders on competing takeover bids, endorsing MIXI’s $1.20 cash offer while highlighting significant uncertainties and lower value in Betr Entertainment’s all-scrip proposal.

Invion Limited has announced a fully underwritten entitlement offer of Loyalty Options to raise capital for advancing its cancer clinical trials. The offer, led by Blue Ocean Equities and supported by CEO Prof Thian Chew, invites eligible shareholders to participate in a non-renounceable rights issue.

Prominence Energy has agreed to acquire a vast natural hydrogen and helium exploration portfolio on the Gawler Craton, backed by a $1.75 million capital raise and strategic board appointments.

Trigg Minerals advances its Antimony Canyon Project with near-term pilot extraction plans and a strategic land expansion linking new mineralised zones in Utah, positioning itself to address critical US antimony supply needs.

Noble Helium Limited has responded to ASX inquiries about recent unusual trading activity, attributing it to ongoing convertible note amendment negotiations but denying undisclosed information influenced the market.

Envirosuite has secured a key regulatory green light from FIRB for its acquisition by Ideagen, moving the proposed Scheme of Arrangement closer to shareholder approval.

Universal Biosensors has requested a voluntary suspension of its shares on the ASX, pending details of a proposed capital raising. The suspension is expected to last until the end of June or until the announcement is made.

Vection Technologies has secured a $2.6 million contract to co-develop SAFE-XR, an AI-powered safety compliance platform using augmented reality and wearable tech for industrial inspections in Italy.

PYC Therapeutics has gained FDA alignment on the design of its pivotal Phase 2/3 trial for VP-001, a promising treatment for the rare childhood blindness RP11. The regulator accepted the trial’s sham control arm and primary endpoints, setting the stage for a critical next step toward drug approval.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Metcash Limited reported solid FY25 financial results with revenue growth and market share gains across key pillars, underpinned by strategic acquisitions and operational improvements. The company enters FY26 with positive momentum and ongoing transformation initiatives.

Eden Innovations is expanding the use of its EdenCrete® concrete additives across major infrastructure projects in Colorado, including a high-rise, public pools, and a massive highway upgrade.